DRKS00022428
Completed
未知
Identification of biomarkers specific to different nicotine product categories - BoEx nicotine product user groups
ABF GmbH0 sites60 target enrollmentJuly 20, 2020
Conditionssmoking
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- smoking
- Sponsor
- ABF GmbH
- Enrollment
- 60
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects meeting all of the criteria listed below will be included in the clinical trial:
- •Between 19 and 65 years of age
- •Males and females
- •Physically and mentally healthy, without a legal guardian
Exclusion Criteria
- •Subjects were excluded from the clinical trial without further ado if any of the following criteria were met at screening or at Day \-1:
- •Dual/multiple use of any other nicotine\-containing product;
- •BMI: \< 18 and \> 33 kg/m2;
- •Pregnant and/or lactating women;
- •Drug abusers;
- •Chronic respiratory or cardiovascular disease like asthma, chronic obstructive pulmonary disease, chronic bronchitis, hypertension (either self\-reported or diagnosed by the investigator);
- •Regular use of medication, excluding hormonal contraceptives and non\-prescription pain medication, prior to study inclusion within the last three months or is intended to do so during the study conduct (The definition of regular use of medication will be based on individual physician discretion).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Identification of biomarkers for diagnosis and prognosis in the patients with obstructive sleep apneaobstructive sleep apneaJPRN-UMIN000021503Osaka university graduate School of medicine The department of geriatric and general medicine200
Active, not recruiting
Not Applicable
Identification of genetic and functional biomarkers that predict PPAR-gamma-associated fluid retention and oedemaEUCTR2008-001634-28-GBniversity of Dundee
Completed
Not Applicable
Identification of biomarkers which reflects the treatments effects of Nivolmab through comprehensive analyses of serum exosmal mRNA derived from the HNSCC patients.head and neck squamous cell cancerJPRN-UMIN000037029Clinical Research Support Center Kyushu111
Recruiting
Not Applicable
Identification of biomarkers sensitive to disease progression in patients with Mild Cognitive Impairment. Two-Part Research: Part BF00.2Alzheimer's diseaseMild Cognitive ImpairmentF00.0F00.1F00.9F06.7Dementia in Alzheimer disease with early onsetDementia in Alzheimer disease with late onsetDementia in Alzheimer disease, atypical or mixed typeDementia in Alzheimer disease, unspecifiedMild cognitive disorderDRKS00003705QUALISSIMA150
Completed
Not Applicable
Identification of biomarkers sensitive to disease progression in patients with Mild Cognitive Impairment: a two-part clinical study. Part A: Multisite MRI Acquisition - Protocol Harmonization Part B: Identification of biomarkers sensitive to disease progression in patients with Mild Cognitive Impairment: a clinical studyNL-OMON38870Vrije Universiteit Medisch Centrum15